Insisting on existential decision as the last word in such an ungroundable sphere is one way of understanding ethical responsibility.

It wharves the wair and stirs the sand.

Irving et al [5 ] recently applied this principle to test the non-ATP competitive Mek1/2 inhibitor selumetinib (AZD6244, ARRY-142886) as monotreatment for childhood ALL in preclinical studies and concluded that clinical evaluation of selumetinib is warranted.

The full ludicrousness of the thing dawned upon me so forcibly that I forgot all about my excitement and scare, and laughed aloud.